<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutations of the FLT3, c-KIT, c-FMS, KRAS, NRAS, BRAF and CEBPA genes in the receptor tyrosine kinase (RTK)/<z:mp ids='MP_0011356'>RAS</z:mp>-BRAF signal-transduction pathway are frequent in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We examined 140 patients with therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) for point mutations of these seven genes </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 11 FLT3, two c-KIT, seven KRAS, eight NRAS and three BRAF mutations were identified in 29 patients (21%) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but one patient with a FLT3 mutation presented with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P=0.0002) </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, FLT3 mutations were significantly associated with previous radiotherapy without chemotherapy (P=0.03), and with a <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype (P=0.004), but inversely associated with previous therapy with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (P=0.003) and with -7/7q- (P=0.001) </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> mutations were associated with AML1 point mutations (P=0.046) and with progression from t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P=0.008) </plain></SENT>
<SENT sid="6" pm="."><plain>Noteworthy, <z:hpo ids='HP_0000001'>all</z:hpo> three patients with BRAF mutations presented as t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> of M5 subtype with t(9;11)(p22;q23) and MLL-rearrangement (P=0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>In t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:mp ids='MP_0011356'>RAS</z:mp>/BRAF mutations were significantly associated with a very short survival (P=0.017) </plain></SENT>
<SENT sid="8" pm="."><plain>Half of the patients with a mutation in the RTK/<z:mp ids='MP_0011356'>RAS</z:mp>-BRAF signal-transduction pathway (denoted 'class-I' mutations) simultaneously disclosed mutation of a hematopoietic transcription factor (denoted 'class-II' mutations) (P=0.046) suggesting their cooperation in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
</text></document>